BioCentury | Feb 9, 2018
Clinical News

ZZ Biotech's 3K3A-APC reduces hemorrhage rate in Phase II for acute ischemic stroke

...that 3K3A-APC significantly reduced the incidence of any hemorrhage vs. placebo (67.4% vs. 86.5%, p=0.046). 3K3A-APC...
...Stroke Conference in Los Angeles. Patients received placebo or 120, 240, 360 or 540 μg/kg 3K3A-APC...
...U.S. trial’s primary endpoint is safety. Secondary endpoints include pharmacokinetics, hemorrhage rate and antibody formation. 3K3A-APC...
BioCentury | Sep 29, 2016
Distillery Therapeutics

Therapeutics: Activated protein C (APC)

...Mouse studies suggest human neuronal stem cell (NSC) grafts combined with the human APC variant 3K3A-APC...
...In a mouse model of middle cerebral artery occlusion, transplants of human fetal NSCs plus 3K3A-APC...
...NSC grafts and 3K3A-APC in other models of stroke and neuronal loss. Socratech LLC has 3K3A-APC...
BioCentury | Apr 18, 2013
Distillery Therapeutics

Indication: Neurology

...engineered APC variants in mouse models for neurodegenerative disease and ischemic stroke. ZZ Biotech LLC's 3K3A-APC...
BioCentury | Aug 13, 2012
Clinical News

3K3A-APC: Phase I started

...720 µg/kg IV 3K3A-APC in about 62 healthy volunteers. Socratech LLC , Rochester, N.Y. Product: 3K3A-APC...
Items per page:
1 - 4 of 4